Last reviewed · How we verify
CetuGEX™
CetuGEX targets the CD137 receptor to stimulate an immune response against cancer cells.
CetuGEX targets the CD137 receptor to stimulate an immune response against cancer cells. Used for Metastatic melanoma.
At a glance
| Generic name | CetuGEX™ |
|---|---|
| Also known as | tomuzotuximab, Tomuzotuximab |
| Sponsor | Glycotope GmbH |
| Drug class | Immune checkpoint inhibitor |
| Target | CD137 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
CetuGEX works by binding to the CD137 receptor, also known as 4-1BB, which is expressed on the surface of activated T cells. This binding activates the receptor, leading to an increase in T cell proliferation and activation, and ultimately, an enhanced immune response against cancer cells.
Approved indications
- Metastatic melanoma
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer (PHASE2)
- CetuGEX™: Phase 1 Study in Cancer Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |